Lilly weekly diabetes drug succeeds vs market leader Victoza -study

An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study. The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday. Dulaglutide, considered one of the more important medicines in Lilly's pipeline of drugs in development, is awaiting U.S. and European approval decisions. "It is our hope that we will have approval this year," Lilly's Senior Medical Director Sherry Martin said in a telephone interview.



via Health News Headlines - Yahoo News http://ift.tt/1dtx2wL